Related Experiment Video
Updated: Feb 28, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Eribulin in advanced liposarcoma and leiomyosarcoma.
Elisabetta Setola1, Jonathan Noujaim2, Charlotte Benson2
1a Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS , Meldola , Italy.
Expert Review of Anticancer Therapy
|June 17, 2017
Summary
Eribulin demonstrates significant overall survival benefits for patients with advanced liposarcoma and leiomyosarcoma. This microtubule-targeting agent shows efficacy in soft tissue sarcomas (STS) with an acceptable safety profile.
Area of Science:
- Oncology
- Pharmacology
- Sarcoma Research
Background:
- Soft tissue sarcomas (STS) exhibit significant heterogeneity, complicating treatment strategies.
- Standard first-line chemotherapy for advanced STS involves doxorubicin, with limited options for subsequent therapies.
- Personalized treatment approaches are crucial for improving outcomes in STS management.
Purpose of the Study:
- To provide an overview of eribulin's efficacy and safety in treating advanced soft tissue sarcomas (STS).
- To compare eribulin's clinical outcomes across different STS histological subtypes.
- To discuss eribulin's mechanisms of action and compare it with other sarcoma treatments.
Main Methods:
- Review of a randomized Phase III clinical trial evaluating eribulin in liposarcoma and leiomyosarcoma.
- Analysis of eribulin's efficacy and safety data in advanced STS.
- Comparison of eribulin with other active agents in sarcoma treatment.
Main Results:
- Eribulin demonstrated an overall survival (OS) advantage in liposarcoma and leiomyosarcoma patients in a Phase III trial.
- Clinical outcomes varied between different histological subtypes of STS treated with eribulin.
- Eribulin exhibits potent microtubule-destabilizing activity and other antitumor effects.
Conclusions:
- Eribulin is an effective treatment option for specific STS populations, including liposarcoma and leiomyosarcoma.
- The drug possesses an acceptable toxicity profile for advanced STS.
- Further research is needed to elucidate eribulin's precise mechanisms and its potential in combination therapies.
